(MEDP) Medpace Holdings - Ratings and Ratios
Clinical Trials, Lab Testing, Regulatory Consulting, Data Management
MEDP EPS (Earnings per Share)
MEDP Revenue
Description: MEDP Medpace Holdings July 25, 2025
Medpace Holdings, Inc. is a leading provider of clinical research-based services for the pharmaceutical, biotechnology, and medical device industries, operating globally across North America, Europe, and Asia. The companys comprehensive suite of services supports the clinical development process from Phase I to Phase IV across various therapeutic areas.
Key aspects of Medpaces service offerings include clinical development services, development plan design, project management, regulatory affairs, clinical monitoring, data management and analysis, and pharmacovigilance. Additionally, they provide bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials, making them a one-stop-shop for clients.
From a financial perspective, Medpace has demonstrated strong performance, with a Return on Equity (RoE) of 54.36%, indicating efficient use of shareholder capital. To further analyze the companys performance, other key performance indicators (KPIs) such as Revenue Growth Rate, Operating Margin, and Debt-to-Equity Ratio could be examined. For instance, a high Revenue Growth Rate would indicate Medpaces ability to expand its client base and increase its market share. An Operating Margin analysis would provide insights into the companys ability to manage costs and maintain profitability. A low Debt-to-Equity Ratio would suggest that Medpace has a healthy balance sheet and is not over-leveraged.
To evaluate the stocks potential, its essential to consider its valuation multiples. With a Price-to-Earnings (P/E) ratio of 23.81 and a Forward P/E of 25.38, Medpaces stock appears to be reasonably valued compared to its earnings. However, a more comprehensive analysis would involve comparing these multiples to industry averages and examining the companys historical valuation trends.
MEDP Stock Overview
| Market Cap in USD | 16,805m |
| Sub-Industry | Life Sciences Tools & Services |
| IPO / Inception | 2016-08-11 |
MEDP Stock Ratings
| Growth Rating | 77.8% |
| Fundamental | 93.7% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | 55.9% |
| Analyst Rating | 3.33 of 5 |
MEDP Dividends
Currently no dividends paidMEDP Growth Ratios
| Growth Correlation 3m | 96.7% |
| Growth Correlation 12m | 34.5% |
| Growth Correlation 5y | 87.5% |
| CAGR 5y | 40.06% |
| CAGR/Max DD 3y (Calmar Ratio) | 1.02 |
| CAGR/Mean DD 3y (Pain Ratio) | 3.04 |
| Sharpe Ratio 12m | 0.75 |
| Alpha | 62.39 |
| Beta | 1.408 |
| Volatility | 37.19% |
| Current Volume | 343.1k |
| Average Volume 20d | 340.7k |
| Stop Loss | 584 (-3.5%) |
| Signal | 1.69 |
Piotroski VR‑10 (Strict, 0-10) 9.0
| Net Income (418.3m TTM) > 0 and > 6% of Revenue (6% = 133.9m TTM) |
| FCFTA 0.37 (>2.0%) and ΔFCFTA 10.70pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -31.35% (prev -5.94%; Δ -25.41pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.39 (>3.0%) and CFO 614.1m > Net Income 418.3m (YES >=105%, WARN >=100%) |
| Net Debt (78.6m) to EBITDA (490.7m) ratio: 0.16 <= 3.0 (WARN <= 3.5) |
| Current Ratio 0.43 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (30.2m) change vs 12m ago -5.99% (target <= -2.0% for YES) |
| Gross Margin 31.62% (prev 28.52%; Δ 3.10pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 127.8% (prev 105.7%; Δ 22.10pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 30.87 (EBITDA TTM 490.7m / Interest Expense TTM 15.4m) >= 6 (WARN >= 3) |
Altman Z'' -3.08
| (A) -0.45 = (Total Current Assets 520.8m - Total Current Liabilities 1.22b) / Total Assets 1.57b |
| (B) -0.45 = Retained Earnings (Balance) -703.2m / Total Assets 1.57b |
| (C) 0.27 = EBIT TTM 475.7m / Avg Total Assets 1.75b |
| (D) -0.51 = Book Value of Equity -708.6m / Total Liabilities 1.40b |
| Total Rating: -3.08 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 93.68
| 1. Piotroski 9.0pt = 4.0 |
| 2. FCF Yield 3.43% = 1.72 |
| 3. FCF Margin 25.98% = 6.49 |
| 4. Debt/Equity 0.72 = 2.25 |
| 5. Debt/Ebitda 0.16 = 2.48 |
| 6. ROIC - WACC (= 44.62)% = 12.50 |
| 7. RoE 67.66% = 2.50 |
| 8. Rev. Trend 96.58% = 7.24 |
| 9. EPS Trend 90.01% = 4.50 |
What is the price of MEDP shares?
Over the past week, the price has changed by +14.61%, over one month by +21.69%, over three months by +32.81% and over the past year by +84.47%.
Is Medpace Holdings a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of MEDP is around 709.28 USD . This means that MEDP is currently undervalued and has a potential upside of +17.2% (Margin of Safety).
Is MEDP a buy, sell or hold?
- Strong Buy: 2
- Buy: 0
- Hold: 10
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the MEDP price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 499.5 | -17.5% |
| Analysts Target Price | 499.5 | -17.5% |
| ValueRay Target Price | 809.7 | 33.8% |
MEDP Fundamental Data Overview October 25, 2025
P/E Trailing = 41.6627
P/E Forward = 36.2319
P/S = 7.53
P/B = 87.3951
P/EG = 4.1374
Beta = 1.408
Revenue TTM = 2.23b USD
EBIT TTM = 475.7m USD
EBITDA TTM = 490.7m USD
Long Term Debt = 124.9m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 23.3m USD (from shortTermDebt, last fiscal year)
Debt = 124.9m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 78.6m USD (from netDebt column, last quarter)
Enterprise Value = 16.88b USD (16.81b + Debt 124.9m - CCE 46.3m)
Interest Coverage Ratio = 30.87 (Ebit TTM 475.7m / Interest Expense TTM 15.4m)
FCF Yield = 3.43% (FCF TTM 579.8m / Enterprise Value 16.88b)
FCF Margin = 25.98% (FCF TTM 579.8m / Revenue TTM 2.23b)
Net Margin = 18.74% (Net Income TTM 418.3m / Revenue TTM 2.23b)
Gross Margin = 31.62% ((Revenue TTM 2.23b - Cost of Revenue TTM 1.53b) / Revenue TTM)
Gross Margin QoQ = 29.84% (prev 31.93%)
Tobins Q-Ratio = 10.74 (Enterprise Value 16.88b / Total Assets 1.57b)
Interest Expense / Debt = 6.31% (Interest Expense 7.88m / Debt 124.9m)
Taxrate = 27.52% (34.3m / 124.5m)
NOPAT = 344.8m (EBIT 475.7m * (1 - 27.52%))
Current Ratio = 0.43 (Total Current Assets 520.8m / Total Current Liabilities 1.22b)
Debt / Equity = 0.72 (Debt 124.9m / totalStockholderEquity, last quarter 172.4m)
Debt / EBITDA = 0.16 (Net Debt 78.6m / EBITDA 490.7m)
Debt / FCF = 0.14 (Net Debt 78.6m / FCF TTM 579.8m)
Total Stockholder Equity = 618.2m (last 4 quarters mean from totalStockholderEquity)
RoA = 26.61% (Net Income 418.3m / Total Assets 1.57b)
RoE = 67.66% (Net Income TTM 418.3m / Total Stockholder Equity 618.2m)
RoCE = 64.01% (EBIT 475.7m / Capital Employed (Equity 618.2m + L.T.Debt 124.9m))
RoIC = 55.77% (NOPAT 344.8m / Invested Capital 618.2m)
WACC = 11.15% (E(16.81b)/V(16.93b) * Re(11.20%) + D(124.9m)/V(16.93b) * Rd(6.31%) * (1-Tc(0.28)))
Discount Rate = 11.20% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -2.64%
[DCF Debug] Terminal Value 71.87% ; FCFE base≈549.0m ; Y1≈677.3m ; Y5≈1.16b
Fair Price DCF = 421.7 (DCF Value 11.88b / Shares Outstanding 28.2m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 90.01 | EPS CAGR: 24.35% | SUE: 1.41 | # QB: 1
Revenue Correlation: 96.58 | Revenue CAGR: 17.88% | SUE: 4.0 | # QB: 2
Additional Sources for MEDP Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle